U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06861777) titled 'Total Neoadjuvant Therapy Combined with Adebrelimab in Locally Advanced Resectable ESCC' on March 03.
Brief Summary: Esophageal cancer is a malignant tumor with high incidence rate and mortality in China. According to the data of the World Health Organization, 324000 new cases and 301000 deaths of esophageal cancer will occur in China in 2020, accounting for 53.70% and 55.35% of the global incidence and death of esophageal cancer respectively.
Surgery is the main method for locally advanced resectable esophageal cancer, combined with chemoradiotherapy(CRT), in order to achieve curative resection. However, after neoadjuvant chemorad...